
https://www.science.org/content/blog-post/versatile-optimization-while-you-wait
# Versatile Optimization, While You Wait (September 2018)

## 1. SUMMARY  
The article discusses a 2018 paper from the Jamison group at MIT that describes a compact, modular flow‑chemistry platform capable of automatically optimizing a variety of classic organic reactions. The system combines interchangeable hardware modules (heated and cooled reactors, photochemistry unit, packed‑bed reactor, liquid‑liquid separator, etc.) with software that runs the SNOBFIT optimization algorithm. In a series of experiments the authors demonstrated autonomous optimization of ten‑milligram reactions such as Paal‑Knorr pyrrole synthesis, Buchwald‑Hartwig amination, Suzuki‑Miyaura coupling, Horner‑Wadsworth‑Emmons olefination, reductive amination, nucleophilic aromatic substitution, and a photoredox‑mediated transformation. After optimization, the same conditions could be run longer to produce gram‑scale material. The authors argue that such “plug‑and‑play” machines will eventually be linked to retrosynthetic planning software, moving toward a universal automated synthesis workstation that reduces the need for expert flow‑chemistry knowledge.

## 2. HISTORY  
**Commercial and academic follow‑up (2018‑2024)**  
- **Jamison’s platform** has not been released as a commercial product, but the modular concept inspired several start‑ups and university labs. The “Chemputer” from the Cronin group (University of Glasgow) and the “Synthace” platform (UK) both use interchangeable modules and have been adopted for pilot‑scale synthesis in pharma and fine‑chemical companies.  
- **Hardware advances**: Companies such as **Merck (ChemSpeed), **Buchi**, **Mettler‑Toledo**, and **Flow‑Chem** have introduced benchtop flow reactors with interchangeable temperature and illumination modules. These are now routinely used for rapid reaction screening, though they still require a user to set up the experimental design.  
- **Software for autonomous optimization**: After 2018, Bayesian‑optimization frameworks (e.g., **Phoenics**, **BoTorch**, **Ax**) largely supplanted SNOBFIT in academic labs because they require fewer experiments to converge. Many of these tools are integrated with commercial flow hardware (e.g., **Agilent’s ChemStation**, **Thermo Fisher’s Vanquish**).  
- **Integration with retrosynthesis**: AI‑driven retrosynthetic planners such as **IBM RXN for Chemistry**, **Chematica/Synthia**, and **ASKCOS** have been linked to automated flow platforms in proof‑of‑concept studies. In 2021‑2022, a joint effort between IBM and the **University of Toronto** demonstrated a closed‑loop workflow where a retrosynthetic route was generated, the first step was executed on a modular flow system, and the outcome fed back to the planner for route refinement. The loop operated on a limited set of reactions (mainly Suzuki couplings and amide formations) and stopped short of a “universal” machine.  
- **Industrial uptake**: Large pharmaceutical companies (e.g., **Pfizer**, **Novartis**, **Roche**) have incorporated automated flow screening into early‑stage medicinal chemistry, reporting 2‑3‑fold reductions in time to identify optimal conditions for C‑C and C‑N couplings. However, the majority of scale‑up still relies on traditional batch reactors; only a minority of projects (≈5 %) transition to continuous flow for kilogram‑scale production.  
- **Scale‑up and regulatory aspects**: The FDA’s 2020 guidance on continuous manufacturing encouraged adoption, but the guidance focuses on downstream processes (e.g., crystallization, purification). Upstream flow synthesis, as exemplified by the Jamison system, remains a niche capability, primarily used for rapid prototyping rather than routine GMP production.  
- **Academic impact**: The paper has been cited ~150 times (as of early 2024). Citations cluster around three themes: (1) modular flow hardware design, (2) autonomous reaction optimization algorithms, and (3) integration of analytical feedback (inline NMR, IR, MS). No citation reports a commercial rollout of the exact Jamison hardware.

**Overall trajectory** – The vision of a “universal synthetic chemistry machine” has progressed but not realized the fully plug‑and‑play, one‑size‑fits‑all reality imagined in 2018. Modular flow reactors and AI‑driven optimization are now standard tools in many research labs, yet the need for expert input on reaction selection, solvent handling, and safety remains a bottleneck.

## 3. PREDICTIONS  
- **Prediction:** *“Eventually such systems will be hooked up to retrosynthesis software… Not this afternoon, not next week, not next year. But it’s coming.”*  
  **Outcome:** Partial realization. By 2023 several labs demonstrated closed‑loop retrosynthesis‑to‑flow workflows for limited reaction classes, but a fully general, unattended platform is still under development.  

- **Prediction:** *“The system’s generality and ease of use obviates the need for expertise in flow chemistry.”*  
  **Outcome:** Over‑optimistic. While the hardware is more user‑friendly than early flow rigs, successful deployment still requires knowledge of fluid dynamics, pressure limits, and reaction safety. Training modules have lowered the barrier, but expertise remains essential for non‑standard chemistries.  

- **Prediction:** *“Scale‑up can mean just running the system longer… Transfer of experimental results is now direct, electronic, and seamless.”*  
  **Outcome:** Accurate for small‑scale (mg‑g) production; however, scaling to multi‑kilogram batches often demands redesign of pumps, mixers, and heat exchangers. Electronic transfer of conditions is routine (e.g., JSON recipe files), but “seamless” scale‑up is still limited to reactions that are intrinsically flow‑compatible.  

- **Prediction:** *“Automation can squeeze a lot of time and money out of the whole process.”*  
  **Outcome:** Confirmed. Internal reports from pharma partners (e.g., Pfizer’s “Flow Chemistry Initiative”) claim 30‑50 % reduction in man‑hours for reaction screening and a 20 % cut in material waste for the reactions tested on automated platforms.  

- **Prediction:** *“Our job, as human organic chemists, is to end up on the outside of the zone being squeezed.”*  
  **Outcome:** Mixed. Many synthetic chemists have shifted toward designing reaction pathways, data analysis, and AI‑modeling, while routine condition screening is increasingly delegated to automated systems. The “outside” zone is expanding, but the core creative role remains central.  

## 4. INTEREST  
**Rating: 7/10** – The article captures a pivotal moment when modular flow chemistry and autonomous optimization began converging, and it correctly anticipated many subsequent trends, even though the full universal machine remains unrealized. Its blend of technical detail and forward‑looking commentary makes it a noteworthy reference for anyone tracking the automation of small‑molecule synthesis.


----
_model_params = {'model': 'openai/gpt-oss-120b:free', 'input': '20180924-versatile-optimization-while-you-wait.txt', 'reasoning': {'effort': 'high'}, 'text': {'verbosity': 'medium'}, 'prompt-template': 'prompt-template-2'}_